Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049972 · ClinicalTrials.gov registry record · Phase 4
Major Depressive Disorder Study In Adults
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 646
- Enrollment target
NCT00049972: Completed Phase 4 study, sponsored by GlaxoSmithKline.
NCT00049972 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 646 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00049972, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 646 participants
- Enrollment target
Study Summary
A study to obtain safety and tolerability data
Interventions
- DRUG paroxetine CR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 646 participants |
| Start Date | 2002-09 |
| Est. Completion | 2003-09 |
| Phase | Phase 4 |
What the finished NCT00049972 record still lists
NCT00049972 is an interventional study that assigns participants to a tested intervention. The registered 646 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (25% higher).
The record links to 0 conditions, and to 1 intervention - of which paroxetine CR is the first listed.
NCT00049972 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00049972 about?
NCT00049972 is a clinical study titled "Major Depressive Disorder Study In Adults". A study to obtain safety and tolerability data
What is the current status of trial NCT00049972?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 646 participants. The study started on 2002-09. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00049972?
The interventions under investigation include: paroxetine CR (DRUG).
Who is sponsoring clinical trial NCT00049972?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00049972's enrollment target sits among peer trials
646 125th of 2000 higher than 1,875 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04863222 · 646 participants · Phase 4
Clinical and Radiographic Success of MTA vs Biodentine
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- NCT07027306 · 648 participants
The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures
- NCT07164456 · 648 participants · NA
Together Stronger: A Family-centered Lifestyle Intervention for Black Prostate Cancer Survivors and Their Caregivers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia